What question did this study set out to answer?

Assess differences in treatment persistence and efficacy between subcutaneous and intravenous infliximab in patients with active inflammatory bowel disease.

January 23, 2026Journal of Crohn s and Colitis

P1017Real-world Comparison of Subcutaneous versus Intravenous Infliximab in Patients with Active Inflammatory Bowel Disease

View Full Paper

Ask AI

Bookmark

Assess differences in treatment persistence and efficacy between subcutaneous and intravenous infliximab in patients with active inflammatory bowel disease.
Prospective observational study
Included patients with active inflammatory bowel disease initiating IFX-IV or IFX-SC
Compared persistence rates, medication use, clinical responses, and biomarkers
83 patients completed follow-up; significant immunosuppressant use in IFX-IV (38.4%) vs. IFX-SC (9.6%)
Higher dose intensification in IFX-IV (40.4%) vs. IFX-SC (3.2%)
Mean drug level was higher in IFX-SC (16.7 µg/mL) compared to IFX-IV (11.3 µg/mL)
No significant differences in clinical efficacy or biomarker outcomes between groups
Patients preferred the IFX-SC route of administration

Authors

IPI González PartidaHospital Universitario Puerta de Hierro Majadahonda RLR De LucasHospital Universitario Puerta de Hierro Majadahonda MCM CalvoHospital San Pedro

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study compares persistence and efficacy of infliximab formulations in patients, suggesting meaningful implications for treatment choice.

Cite This Study

Partida et al. (2026) studied this question.

synapsesocial.com/papers/697310b0c8125b09b0d205aa https://doi.org/10.1093/ecco-jcc/jjaf231.1198

View Full Paper

Ask AI

Bookmark

Implication

Observational study compares persistence and efficacy of infliximab formulations in patients, suggesting meaningful implications for treatment choice.

P1017Real-world Comparison of Subcutaneous versus Intravenous Infliximab in Patients with Active Inflammatory Bowel Disease

Key Points

Discussion

Implication

Cite This Study

P1017Real-world Comparison of Subcutaneous versus Intravenous Infliximab in Patients with Active Inflammatory Bowel Disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider